GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: Placebo (Normal Saline)
Biological: GSK3888550A RSV Maternal vaccine formulation 1
Biological: GSK3888550A RSV Maternal vaccine formulation 3
Biological: GSK3888550A RSV Maternal vaccine formulation 2

First Posted Date: 2018-09-17

Last Posted Date: 2021-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 502

Registration Number: NCT03674177

Locations: 🇩🇪
GSK Investigational Site, Hamburg, Germany

A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea

Completed

Conditions: Neoplasms, Rectal

Interventions: Other: Safety data collection (following routine vaccination) by a continuous surveillance method.

First Posted Date: 2018-09-14

Last Posted Date: 2023-02-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 670

Registration Number: NCT03671369

Locations: 🇰🇷
GSK Investigational Site, Yangju-si, Gyeonggi-do, Korea, Republic of

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: GSK3368715

First Posted Date: 2018-09-12

Last Posted Date: 2022-05-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 31

Registration Number: NCT03666988

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Phase 2

Completed

Conditions: Infections, Meningococcal

Interventions: Biological: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Biological: Licensed GSK MenACWY vaccine (Menveo)

First Posted Date: 2018-08-29

Last Posted Date: 2021-02-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 996

Registration Number: NCT03652610

Locations: 🇮🇹
GSK Investigational Site, Massafra (TA), Italy

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Phase 1

Completed

Conditions: Autoimmune Diseases

Interventions: Drug: GSK2982772 Modified Release
Drug: GSK2982772 Immediate Release

First Posted Date: 2018-08-28

Last Posted Date: 2020-05-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 33

Registration Number: NCT03649412

Locations: 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom

A Clinical Study to Investigate the Dermal and Ocular Tolerance of a Developmental Cosmetic Facial Serum Formulation in Healthy Females With Sensitive Skin

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Developmental Serum
Other: Physiogel Calming Relief Anti-Redness Serum

First Posted Date: 2018-08-21

Last Posted Date: 2020-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 90

Registration Number: NCT03640832

Locations: 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV (GSK3389245A) lower dose formulation vaccine
Biological: RSV (GSK3389245A) higher dose formulation vaccine
Biological: GSK's multicomponent meningococcal B vaccine
Biological: Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine
Biological: GSK's pneumococcal polysaccharide conjugate vaccine
Biological: GSK's meningococcal group A, C, W-135 and Y conjugate vaccine
Drug: Placebo